Company Status

Company Status

Having demonstrated our technology and raised our initial seed capital, LUMABS BV is currently looking to expand the breadth of antibodies/antigens for which we have developed corresponding LUMABS and RAPPID reagents. Therefore, we encourage potential partners who are developing novel immunoassays (such as therapeutic antibodies), or already have them in the clinic and/or market already, and have a need for updated bioanalysis tools (such as moving from a Heterogeneous ELISA format to a Homogeneous one) to gain a competitive edge in the marketplace, to contact us to discuss their needs and the solutions LUMABS BV Technological Platform can offer. This will be done in confidence as required.

Investment opportunity

Lumabs BV will soon open a new funding round to accelerate the Assay Development of novel Bioluminescence Immuno-Diagnostics:

  • Revolution in Point of Care diagnostics – our patented RAPPID Technology Platform for Bioluminescence-based quantitative immunodiagnostics combines laboratory accuracy with OTC convenience

  • Disruptive market approach – our RAPPID Technology Platform for Bioluminescence-based quantitative immunodiagnostics opens previously laboratory-based markets for self-testing. Our financial forecast and business plan has clear exit opportunities for investors

  • Operating in highly attractive markets – high growth with strong, unmatched diagnostic need

  • First product launch based on the RAPPID Technology Platform is expected in 2025 – far more in the pipeline

  • Strong management and enthusiastic R&D team – strong industry and academic credentials

Are you an Environmental, Social, and Governance (ESG) and/or Impact Funding Investor?

Here are some of the reasons why LUMABS BV is the perfect investment opportunity for your goals:

  • Clear policies and impacts on an environmental, social, and governance framework
  • Reduce laboratory waste at Hospitals, Clinics and Diagnostic Laboratories:
    • Problem: of the 1.3 tons/day per hospital, up to 20% is due to the use of plastics from diagnostic products as well as dispose of solutions
    • Devices, usually made of unsustainable plastics, often need to be incinerated to reduce infection risk, creating an additional release of greenhouse gas and, potentially, other pollutants.
    • By adopting our technology, previous ELISA assay manufacturers can reduce in >100x fold the amount of plastic parts and liquid washing solutions used in standard ELISA assay methodologies
  • Our company has implemented policies that promote ethical and socially conscious themes including diversity, inclusion, community-focus, social justice, and corporate ethics, in addition to fighting against racial, gender, and sexual discrimination.
  • Our technology addresses UN’s GOAL
    • 3: GOOD HEALTH AND WELL-BEING – Ensuring healthy lives and promoting the well-being for all at all ages.
    • 12: RESPONSIBLE CONSUMPTION AND PRODUCTION: Ensure sustainable consumption and production patterns
      • 12.4 By 2020, achieve the environmentally sound management of chemicals and all wastes throughout their life cycle, in accordance with agreed international frameworks, and significantly reduce their release to air, water and soil in order to minimize their adverse impacts on human health and the environment
      • 12.5 By 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse

Join us on our journey. Please contact our CEO Antonio Soares

Publication

Publications from our founding scientist team regarding LUMABS and RAPPID technologies:

  • E.A. van Aalen, S.F.A. Wouters, D. Verzijl, M. Merkx
    Bioluminescent RAPPID Sensors for the Single-Step Detection of Soluble Axl and Multiplex Analysis of Cell Surface Cancer Biomarkers
    Anal. Chem (2022) 94, 6548–6556

  • R. Shimazu, K. Tomimuro, Y. Ni, C. Malegori, V. Hamedpour, Y. Hiruta, P. Oliveri, M. Merkx, D. Citterio
    Microfluidic thread-based analytical devices for point-of-care detection of therapeutic antibody in blood
    Sensors and Actuators B (2022), 352, 121002

  • Y. Ni, B.J.H.M. Rosier, E.A. van Aalen, E.T.L. Hanckmann, L. Biewenga, A.-M. Makri Pistikou, B. Timmermans, C. Vu, S. Roos, R. Arts, W. Li, T.F.A. de Greef, M.M.G.J. van Borren F.J.M. van Kuppeveld, B.-J. Bosch, M. Merkx
    A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays
    Nature Communications (2021) 12, 4586

  • C. Yang, F. Sesterhenn, J. Bonet, E. van Aalen, L. Scheller, L. A .Abriata, J. T. Cramer, X. Wen, S. Rosset, S. Georgeon, T. Jardetzky, T. Krey, M. Fussenegger, M. Merkx, B. E. Correia
    A bottom-up approach for the de novo design of functional proteins
    Nature Chem. Biol. (2021) 17, 492-500

  • K. Tomimuro, K. Tenda, Y. Ni, Y. Hiruta, M. Merkx, D. Citterio
    Thread-based bioluminescent sensor for detecting multiple antibodies in a single drop of whole blood
    ACS Sensors (2020) 5, 6, 1786–1794

  • Y. Ni, R. Arts, M. Merkx
    Ratiometric bioluminescent sensor proteins based on intramolecular split luciferase complementation
    ACS Sensors (2019) 4, 20-25

  • K. Tenda, B. van Gerven, R. Arts, Y. Hiruta, M. Merkx, D. Citterio
    Paper-based antibody detection devices using bioluminescent BRET-switching sensor proteins
    Angew. Chem. Int. Ed. (2018) 57, 15369-15373

  • M. van Rosmalen, Y. Ni, D.F.M. Vervoort, R. Arts, S.K.J. Ludwig, M. Merkx
    Dual color bioluminescent sensor proteins for therapeutic drug monitoring of anti-tumor antibodies
    Anal. Chem. (2018), 90, 3592-3599

  • R. Arts, S.K.J. Ludwig, B.C.B. van Gerven, E. Magdalena Estirado, L.-G. Milroy, M. Merkx
    Semisynthetic bioluminescent sensor proteins for direct detection of antibodies and small molecules in solution
    ACS Sensors (2017), 2, 1730-1736
  • R. Arts, I. den Hartog, S. Zijlema, V. Thijssen, S. v.d. Beelen, M. Merkx
    Detection of antibodies in blood plasma using bioluminescent sensor proteins and a smartphone
    Anal. Chem. (2016) 88, 4525-4531